Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ANGION BIOMEDICA CORP.

(ANGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Angion Biomedica : Termination of Material Definitive Agreement (Form 8-K)

08/30/2021 | 07:12am EDT
Termination of Material Definitive Agreement

On August 27, 2021, Angion Biomedica Corp. ('Angion') received written notice from Sinovant Sciences HK Limited ('Sinovant') that on November 25, 2021 Sinovant intends to terminate its exclusive license agreement with Angion dated August 22, 2018 (the 'Agreement'), pursuant to which Sinovant is responsible for the clinical development and, if approved, commercialization of ANG-3777 for all indications within Greater China.

Specifically, Sinovant informed Angion that its decision to terminate the Agreement is in no way related to the clinical development or economic potential for ANG-3777 in Greater China but is entirely due to a change in Sinovant's strategic direction. Based upon the terms of the Agreement, Sinovant must provide Angion ninety days written notice to Angion prior to termination. There are no fees, payments, or other financial remuneration due to either Angion or Sinovant resulting from the termination of the Agreement.

Angion is evaluating its strategic options to maximize the value of the clinical development and commercialization rights for ANG-3777 in Greater China, including engaging in ongoing discussions with potential partners.




Disclaimer

Angion Biomedica Corporation published this content on 30 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 August 2021 11:11:02 UTC.


© Publicnow 2021
All news about ANGION BIOMEDICA CORP.
10/18ANGION BIOMEDICA : to Present Multiple Posters at Kidney Week 2021
AQ
09/08ANGION BIOMEDICA : Hosting Research & Development Day on ANG-3070 for the Treatment of Lun..
AQ
09/02ANGION BIOMEDICA : to Participate in Upcoming September Investment Conferences
AQ
08/30ANGION BIOMEDICA : Termination of Material Definitive Agreement (Form 8-K)
PU
08/30ANGION BIOMEDICA CORP. : Termination of a Material Definitive Agreement (form 8-K)
AQ
08/30Sinovant Sciences HK Limited Intends to Terminate Its Exclusive License Agreement with ..
CI
08/12ANGION BIOMEDICA : Provides Corporate Update and Reports Second Quarter 2021 Financial Res..
PU
08/12ANGION BIOMEDICA : Earnings Flash (ANGN) ANGION BIOMEDICA Reports Q2 Loss $-0.58
MT
08/12ANGION BIOMEDICA : Earnings Flash (ANGN) ANGION BIOMEDICA Reports Q2 Revenue $540,000
MT
08/12ANGION BIOMEDICA CORP. : Results of Operations and Financial Condition, Financial Statemen..
AQ
More news
Analyst Recommendations on ANGION BIOMEDICA CORP.
More recommendations
Financials (USD)
Sales 2021 3,30 M - -
Net income 2021 - - -
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 255 M 255 M -
Capi. / Sales 2021 77,5x
Capi. / Sales 2022 19,4x
Nbr of Employees 72
Free-Float 59,4%
Chart ANGION BIOMEDICA CORP.
Duration : Period :
Angion Biomedica Corp. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 8,57 $
Average target price 59,33 $
Spread / Average Target 592%
Managers and Directors
Jay R. Venkatesan President, Chief Executive Officer & Director
Greg S. Curhan Chief Financial Officer
Itzhak D. Goldberg Executive Chairman & Chief Scientific Officer
John F. Neylan Chief Medical Officer & Senior Vice President
Jennifer J. Rhodes Secretary, Chief Compliance Office & Senior VP
Sector and Competitors
1st jan.Capi. (M$)
ANGION BIOMEDICA CORP.0.00%255
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455